CoChat

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Abstract

Background Despite the prognostic value of metabolic syndrome for predicting cardiovascular events, few trials have investigated the effects of statin therapy on cardiovascular morbidity and mortality in patients with the metabolic syndrome. Our post hoc analysis of the Treating to New Targets (TNT) study assessed whether intensive lowering of low-density lipoprotein cholesterol with high-dose atorvastatin therapy results in cardiovascular benefits for patients with both coronary heart disease and the metabolic syndrome. Methods The TNT study was a prospective, double blind, parallel-group trial done at 256 sites in 14 countries between April, 1998, and August, 2004, with a median follow-up of 4.9 years. 10,001 patients were enrolled aged 35-75 years with clinically evident coronary heart disease. Our analysis includes 5584 patients with metabolic syndrome based on the 2005 NCEP ATP III criteria. Patients were randomly assigned to receive either atorvastatin 10 mg per day (n=2820) or 80 mg per day (n=2764). The primary outcome measure was time to first major cardiovascular event, defined as death from coronary heart disease, non-fatal non-procedure-related myocardial infarction, resuscitated cardiac arrest, or fatal or non-fatal stroke. Findings In patients with coronary heart disease and metabolic syndrome, mean on-treatment low-density lipoprotein cholesterol concentrations at 3 months were 2.6 mmol/L (99.3 mg/dL) with atorvastatin 10 mg, and 1.9 mmol/L (72.6 mg/dL) with at…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(06)69292-1

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Cited by

See all 387

Metadata

Authors
Deedwania, P., Barter, P., Carmena, R., Fruchart, J.-C., Grundy, S. M., Haffner, S., Kastelein, J. J., LaRosa, J. C., Schachner, H., Shepherd, J., & Waters, D. D.
Affiliations
  • University of California, San Francisco (US)
  • The Heart Research Institute (AU)
  • Universitat de València (ES)
  • Institut Pasteur de Lille (FR)
  • The University of Texas Southwestern Medical Center (US)
  • The University of Texas at San Antonio Health Science Center (US)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • State University of New York (US)
  • Pfizer (United States) (US)
  • University of Glasgow (GB)
  • San Francisco General Hospital (US)
Corresponding author
Deedwania, Prakash
Venue
The Lancet
Publisher
Elsevier BV
Published
2006-09
Volume
368
Issue
9539
Pages
919-928
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2114027342
Cited by
387
References
31
Citations by year
2026: 3 · 2025: 4 · 2024: 2 · 2023: 7 · 2022: 7 · 2021: 1 · 2020: 10 · 2019: 10 · 2018: 16 · 2017: 9 · 2016: 9 · 2015: 16 · 2014: 19 · 2013: 28 · 2012: 16
FWCI
54.06
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
atorvastatin, high-intensity statin therapy, metabolic syndrome, coronary artery disease, major adverse cardiovascular events, cardiovascular risk reduction, LDL cholesterol targets, statin dose comparison, cardiovascular mortality, myocardial infarction, stroke, cardiac arrest, NCEP ATP III criteria, secondary prevention, post hoc analysis
MeSH terms
Atorvastatin, Adult, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Dose-Response Relationship, Drug, Double-Blind Method, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Risk Factors, Metabolic Syndrome, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. https://app.cochat.ai/papers/10.1016/s0140-6736(06)69292-1
The paper
Deedwania, P., Barter, P., Carmena, R., Fruchart, J.-C., Grundy, S. M., Haffner, S., Kastelein, J. J., LaRosa, J. C., Schachner, H., Shepherd, J., & Waters, D. D. (2006). Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. The Lancet. https://doi.org/10.1016/s0140-6736(06)69292-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.